Optiver Holding
ELVN icon

Optiver Holding’s Enliven Therapeutics ELVN Stock Holding History

Optiver Holding’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1K Buy
+219
New +$9.3K ﹤0.01% 1716
2026
Q1 		– Sell
-64
Closed -$986 – 2438
2025
Q4 		$986 Sell
64
-44
-41% -$877 ﹤0.01% 2217
2025
Q3 		$2.21K Buy
+108
New +$2.18K ﹤0.01% 2345

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Optiver Holding's ELVN Position: Q2 2026 in Review

Optiver Holding opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 219 shares worth $11.1K. The stake represents ﹤0.01% of the portfolio and ranks #1716 among its holdings. This is a return to the name: Optiver Holding previously reported a position in ELVN as recently as Q4 2025.

Optiver Holding first reported a position in ELVN in Q3 2025 and has held it in 3 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Optiver Holding held 219 shares of Enliven Therapeutics worth $11.1K as of Q2 2026.
  • Enliven Therapeutics was a new Optiver Holding position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1716 holding.
  • Optiver Holding first reported a position in Enliven Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.